SCHEMBL7737558

SCHEMBL7737558

CC(C)(C)c1cccc(-c2cccc(C(N)=O)c2NCc2ccncc2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.47
FLT1 P17948 7/20 0.47
CDC7 O00311 2/20 0.44
ROCK2 O75116 2/20 0.44
MAP4K4 O95819 2/20 0.44
GSK3B P49841 2/20 0.44
CLK4 Q9HAZ1 2/20 0.44
MKNK2 Q9HBH9 1/20 0.44
KIF11 P52732 1/20 0.44
ABL1 P00519 2/20 0.43
CSF1R P07333 2/20 0.43
PDGFRB P09619 2/20 0.43
KIT P10721 2/20 0.43
FLT4 P35916 2/20 0.43
EGFR P00533 1/20 0.43
RET P07949 1/20 0.41
IGF1R P08069 1/20 0.41
FGFR1 P11362 1/20 0.41
TEK Q02763 1/20 0.41
PIM1 P11309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7732439 0.89 KDR (0.55) KDRFLT1ROCK2GSK3BCLK4
SCHEMBL7739239 0.86 CDC7 (0.48) KDRFLT1CDC7ROCK2MAP4K4
SCHEMBL7738450 0.82 RET (0.55) KDRFLT1CDC7ROCK2MAP4K4
SCHEMBL6131490 0.81 GSK3B (0.48) KDRCDC7ROCK2MAP4K4GSK3B
SCHEMBL5694501 0.80 ROCK2 (0.47) KDRFLT1CDC7ROCK2MAP4K4
SCHEMBL7739127 0.79 RPS6KB1 (0.50) KDRFLT1ABL1CSF1RPDGFRB
SCHEMBL7460271 0.78 CDC7 (0.46) KDRCDC7ROCK2MAP4K4GSK3B
SCHEMBL7739113 0.76 CDC7 (0.43) KDRFLT1CDC7ROCK2MAP4K4
SCHEMBL6680013 0.76 CDC7 (0.40) KDRFLT1CDC7ROCK2MAP4K4
Hydrochloric Acid SCHEMBL9960799 0.76 CDC7 (0.46) KDRFLT1CDC7ROCK2MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020019414-A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors NOVARTIS AG (CH) 2002-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019414-A1 N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors AXL, TYRO3, KDR KDR 3/4885FLT1 6/4885CDC7 3304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.